title: Expression of eag1 channel associated with the aggressive clinicopathological features and subtype of breast cancer.
abstract: BACKGROUND
  Expression of eag1 channel (Eag1) is associated with cell malignant transformation, tumor cell metastasis and poor prognosis of the patient. This study aimed at examining whether expression of the Eag1 associated with aggressive clinicopathological feature and the molecular subtype of breast cancer.
  
  
  METHODS
  109 patients who received breast cancer operation during January 2009 to December 2010 in Chinese-Japanese Friendship Hospital of Jilin University were recruited. We investigated the association of the Eag1 with clinicopathological features and molecular subtype of in triple negative breast cancer (TNBC) by univariate or multivariate analysis in a cross-section study.
  
  
  RESULTS
  The positive rate of Eag1 was 18.5% higher in TNBC compared with non-triple negative breast cancer (Non-TNBC) (P = 0.012, OR = 2.83, 95% CI = 2.16-3.47). Compared with the Eag1 negative group, the expression of Eag1 was linked to the larger tumor size (P = 0.002), advanced TNM stage (P = 0.029), high proportion of positive lymph node (87.6% vs. 65%, P = 0.014) and invasive ductal carcinoma (91% vs. 75%, P = 0.046).
  
  
  CONCLUSIONS
  The expression of Eag1 may be partially explained the aggressive behavior of TNBC in the breast cancer tissue.
authors.affiliation: Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical UniversityBeijing 100069, China; Beijing Municipal Key Laboratory of Clinical EpidemiologyBeijing 100069, China; Physical Examination Center, 731 Hospital, China Aerospace Science and Industry CorporationBeijing, China.
authors.forename: Guang-Xu
authors.initials: GX
authors.lastname: Liu
authors.affiliation: Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical UniversityBeijing 100069, China; Beijing Municipal Key Laboratory of Clinical EpidemiologyBeijing 100069, China.
authors.forename: Yun-Cui
authors.initials: YC
authors.lastname: Yu
authors.affiliation: Center of Prevention and Cure of Breast Diseases, Haidian Maternal & Child Health Hospital Beijing 100080, China.
authors.forename: Xiang-Ping
authors.initials: XP
authors.lastname: He
authors.affiliation: Department of General Surgery, China-Japan Union Hospital of Jilin University Changchun 130021, Jilin, China.
authors.forename: Sheng-Nan
authors.initials: SN
authors.lastname: Ren
authors.affiliation: Department of General Surgery, China-Japan Union Hospital of Jilin University Changchun 130021, Jilin, China.
authors.forename: Xue-Dong
authors.initials: XD
authors.lastname: Fang
authors.affiliation: Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical UniversityBeijing 100069, China; Beijing Municipal Key Laboratory of Clinical EpidemiologyBeijing 100069, China.
authors.forename: Fen
authors.initials: F
authors.lastname: Liu
authors.affiliation: Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical UniversityBeijing 100069, China; Beijing Municipal Key Laboratory of Clinical EpidemiologyBeijing 100069, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: He
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D001943:Breast Neoplasms / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000473:pathology*; D003430:Cross-Sectional Studies; D051638:Ether-A-Go-Go Potassium Channels / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D064726:Triple Negative Breast Neoplasms / Q000473:pathology*
chemical_list: D014408:Biomarkers, Tumor; D051638:Ether-A-Go-Go Potassium Channels; C496884:KCNH1 protein, human
keywords: Eag1 channel; association; clinicopathological features; triple negative breast cancer
references.citation: EMBO J. 1999 Oct 15;18(20):5540-7
references.pmid: 10523298
references.citation: J Membr Biol. 1999 Sep 15;171(2):107-15
references.pmid: 10489423
references.citation: Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2886-91
references.pmid: 16477030
references.citation: J Clin Oncol. 2005 Feb 20;23(6):1152-60
references.pmid: 15718311
references.citation: Cancer Manag Res. 2010 Jan 07;2:13-25
references.pmid: 21188093
references.citation: Zhonghua Yu Fang Yi Xue Za Zhi. 2012 Nov;46(11):1009-14
references.pmid: 23363922
references.citation: Neurosci Lett. 2004 Sep 30;368(3):249-53
references.pmid: 15364405
references.citation: World J Gastroenterol. 2007 Feb 28;13(8):1257-61
references.pmid: 17451210
references.citation: Mol Cancer. 2006;5:41
references.pmid: 17022810
references.citation: Mol Cancer. 2006;5:42
references.pmid: 17022811
references.citation: J Clin Oncol. 2011 Nov 10;29(32):4273-8
references.pmid: 21990413
references.citation: Diagn Pathol. 2010;5:78
references.pmid: 21138547
references.citation: Clin Cancer Res. 2010 Nov 1;16(21):5222-32
references.pmid: 20837693
references.citation: J Clin Oncol. 2006 May 10;24(14):2137-50
references.pmid: 16682732
references.citation: Breast. 2012 Feb;21(1):50-7
references.pmid: 21865043
references.citation: Mol Cancer. 2010;9:18
references.pmid: 20105281
references.citation: Ann Oncol. 2010 Oct;21(10):1974-81
references.pmid: 20332136
references.citation: J Mol Med (Berl). 2012 Oct;90(10):1173-84
references.pmid: 22466864
references.citation: J Clin Oncol. 2009 Mar 10;27(8):1168-76
references.pmid: 19204205
references.citation: J Biol Chem. 2008 Dec 26;283(52):36234-40
references.pmid: 18927085
references.citation: Mol Clin Oncol. 2014 Mar;2(2):245-251
references.pmid: 24649341
references.citation: J Natl Cancer Inst. 2008 Oct 1;100(19):1339-41
references.pmid: 18812546
references.citation: Dig Dis Sci. 2008 Aug;53(8):2039-44
references.pmid: 18080766
references.citation: J Natl Cancer Inst. 2009 May 20;101(10):736-50
references.pmid: 19436038
references.citation: Med Oncol. 2007;24(3):345-50
references.pmid: 17873312
references.citation: Cancer Res. 2009 Apr 15;69(8):3300-7
references.pmid: 19351862
references.citation: Cancer Res. 2004 Oct 1;64(19):6996-7001
references.pmid: 15466192